A Director at Atara Biotherapeutics (ATRA) is Selling Shares


Yesterday, a Director at Atara Biotherapeutics (ATRA), Carol Giltner Gallagher, sold shares of ATRA for $777.6K.

See today’s analyst top recommended stocks >>

Currently, Atara Biotherapeutics has an average volume of 747.6K.

The insider sentiment on Atara Biotherapeutics has been positive according to 97 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Carol Giltner Gallagher’s trades have generated a 147.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts